Metoprine

Metoprine

SCHEMBL3681

Cc1nc(N)nc(N)c1-c1ccc(Cl)c(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
IKBKB O14920 2/20 0.54
MAP3K14 Q99558 2/20 0.54
DHFR P00374 1/20 0.51
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HIF1A Q16665 1/20 0.46
REN P00797 1/20 0.45
KMO O15229 1/20 0.45
NCOA1 Q15788 1/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Metoprine SCHEMBL29463675 1.00 NPC1 (0.54) NPC1RAB9AIKBKBMAP3K14DHFR
Metoprine SCHEMBL4529657 0.98 NPC1 (0.53) NPC1RAB9AIKBKBMAP3K14DHFR
SCHEMBL10999078 0.89 ALDH1A1 (0.48) NPC1RAB9AIKBKBMAP3K14DHFR
SCHEMBL4535505 0.83 HRH4 (0.47) DHFRKMO
SCHEMBL7271200 0.83 HEXA (0.42) NPC1RAB9ADHFRTP53CYP1A2
SCHEMBL7271143 0.83 HEXA (0.42) NPC1RAB9ADHFRTP53CYP1A2
SCHEMBL6049552 0.81 IKBKB (0.49) NPC1RAB9AIKBKBMAP3K14DHFR
SCHEMBL11593238 0.81 KMT2A (0.63) NPC1RAB9AIKBKBMAP3K14DHFR
SCHEMBL9485648 0.80 NCOA1 (0.72) DHFRTP53CYP1A2CYP3A4CYP2D6
Etoprine SCHEMBL3919 0.80 DHFR (0.70) DHFRTP53CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 11181 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122008213-A Humanoid variable impedance control method based on man-machine stiffness mapping 西安交通大学 2026-05-12 CN claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
US-20250275946-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2025-09-04 US claimed
US-20250213523-A1 COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) 2025-07-03 US claimed
EP-4524131-A1 SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH AlonBio Ltd. (IL) 2025-03-19 EP claimed
EP-4504165-A1 COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (IT) 2025-02-12 EP claimed
US-12202803-B2 Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death ALONBIO LTD. (IL) 2025-01-21 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
US-12109219-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2024-10-08 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
CN-1634584-A Anti-cancer medicine composition containing antimetabolite SHANDONG LANJIN BIOENGINEERING (CN) 2005-07-06 CN claimed
EP-1477165-A2 Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis Cornell Research Foundation, INC. (US) 2004-11-17 EP claimed
US-20040092583-A1 Treatment for inhibiting neoplastic lesions SHANAHAN-PRENDERGAST ELIZABETH (IE) 2004-05-13 US claimed
EP-1351678-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS Shanahan-Prendergast, Elizabeth (IE) 2003-10-15 EP claimed
WO-2002053138-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS SHANAHAN-PRENDERGAST ELISABETH (IE) 2002-07-11 WO claimed
EP-1154787-A2 SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES Institute of Molecular and Cell Biology (SG) 2001-11-21 EP claimed
WO-2000050064-A2 SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES INSTITUTE OF MOLECULAR AND CELL BIOLOGY (SG) 2000-08-31 WO claimed
US-4005204-A Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine BURROUGHS WELLCOME CO. (US) 1977-01-25 US claimed
US-4005203-A Treatment of meningeal leukemia with diamino dichlorophenyl pyrimidine BURROUGHS WELLCOME CO. (US) 1977-01-25 US claimed